Victor Chang Cardiac Research Institute, one of the world’s leading medical research organisations, has developed HeartSight, a new AI-powered application designed to support the assessment of aortic stenosis, using Oracle AI Database 26ai and Oracle Cloud Infrastructure (OCI) Data Science. In this early pilot phase, HeartSight has demonstrated promising initial results, with reductions in aortic stenosis diagnosis time of more than 80 percent and imaging data volumes of approximately 95 percent, pointing towards meaningful improvements in the speed, accuracy and consistency of patient diagnosis.

Founded in 1994, Victor Chang Cardiac Research Institute is dedicated to finding cures for cardiovascular disease through world-class and cutting-edge medical research. Aortic stenosis, one of the most common and serious forms of heart valve disease, is a key focus of the Institute’s research as early, accurate diagnosis is critical to improving patient outcomes. To address the time and scalability constraints of manual interpretation, the Institute developed HeartSight, a secure, cloud-native application designed to automate echocardiogram video analysis and broaden access to its aortic stenosis expertise. HeartSight is being built on Oracle AI Database 26ai and OCI Data Science, so that the analysis can be delivered securely, at scale, and with full auditability – laying the foundation for future clinical validation and broader deployment across Australia and internationally.

“At Victor Chang Cardiac Research Institute, our purpose is to improve the lives of people with heart disease through world-class research and clinical impact, and technology is central to turning discovery into better patient outcomes,” said Associate Professor Mayooran Namasivayam, Head, Heart Valve Disease and Artificial Intelligence Laboratory, Victor Chang Cardiac Research Institute. “HeartSight represents an important and exciting first step in that journey. The early pilot results are highly encouraging, and Oracle provides the secure, integrated platform we need to rigorously develop, validate, and scale this work. We are committed to the full validation pathway ahead, and these initial findings give us confidence that combining expert clinical insight with trusted AI has the potential to meaningfully improve the speed and consistency of care for patients with aortic stenosis.”

Built with Oracle AI APEX, Oracle’s low-code application development platform, HeartSight runs on Oracle AI Database 26ai, enabling the Institute to embed AI directly into its core data architecture while securely managing data across multiple locations. Clinicians upload echocardiogram videos and patient parameters to HeartSight, where the data is securely stored in OCI Storage and processed using OCI Data Science to remove patient’s identity information. OCI Data Science provides the governance, reproducibility, and enterprise-grade security required to support clinical research and trusted diagnostic workloads.

“Across the healthcare sector, data and AI are being used to help clinicians deliver more timely, accurate, and personalised care for patients,” said Stephen Bovis, regional managing director, Australia and New Zealand, Oracle. “By building the application on Oracle AI Database 26ai and OCI Data Science, Victor Chang Cardiac Research Institute is taking an exciting first step toward transforming clinical practice from labour-intensive manual analysis to AI-augmented insight. We look forward to supporting the Institute through the rigorous validation stages ahead as it works towards delivering more accurate diagnoses and allowing clinicians to focus on complex decisions and delivering high-quality patient care.”

Oracle Consulting Australia is the implementation partner.